Funding for this research was provided by:
Ontario HIV Treatment Network (RFA G842A)
Canadian Institutes of Health Research (CBR 134793)
Received: 15 September 2017
Accepted: 19 February 2018
First Online: 27 February 2018
Ethics approval and consent to participate
: The study was approved by the Research Ethics Boards of St. Michael’s Hospital, Ryerson University, and the University of Toronto. Informed consent was obtained prior to the collection of study data.
: Not applicable.
: DHST has received honoraria from Merck, Abbvie, Gilead and Viiv Healthcare for developing educational lectures; investigator-driven grants from Gilead and Viiv Healthcare; and clinical trial contracts from Gilead and GSK. The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.